Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6468650

COc1cc(OC)c2nc(Nc3nc(O)c4c(O)cccc4n3)nc(C)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
ALDH1A1 P00352 6/20 0.38
MAPT P10636 5/20 0.38
MEN1 O00255 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
MAPK1 P28482 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 2/20 0.37
G6PD P11413 1/20 0.37
MCL1 Q07820 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 6/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TDP2 O95551 1/20 0.35
POLB P06746 2/20 0.35
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6467073 0.94 KMT2A (0.39) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6468695 0.89 AURKA (0.38) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6470070 0.89 KMT2A (0.36) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
SCHEMBL6468658 0.87 KMT2A (0.36) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6470460 0.86 KMT2A (0.35) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
SCHEMBL6468652 0.86 MAPT (0.36) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6470553 0.85 GAA (0.42) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6470355 0.84 KMT2A (0.35) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6470578 0.84 TDP2 (0.46) KMT2AALDH1A1MAPTMEN1SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6469119 0.83 KDM4E (0.39) KMT2AALDH1A1MAPTMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB KMT2A 2156/4885ALDH1A1 3154/4885MAPT 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.